Potential Ban on Menthol Cigarettes in the US

Jul.05.2022
Potential Ban on Menthol Cigarettes in the US
A proposed ban on menthol-flavored tobacco products in the US could result in 16,250 fewer tobacco-related deaths by 2060.

In April of last year, the US Food and Drug Administration (FDA) announced a proposed ban on menthol-flavored cigarettes and cigars. This was seen as a measure that could significantly reduce smoking rates.


A recent study published in the BMJ Tobacco Control has concluded that a ban on menthol cigarettes could prevent 16,250 tobacco-related deaths annually by 2060. Epidemiology professor Rafael Meza from the University of Michigan School of Public Health stated that "This work is part of a series of projects aimed at evaluating the impact of a menthol ban on smoking and health. Our findings demonstrate significant health benefits from a menthol ban and emphasize the urgency of its eventual approval and implementation.


The investigation results were based on an analysis of compiled data and computational modeling infrastructure from a portion of the Tobacco Regulatory Science Center. The research team utilized traditional cigarette and electronic cigarette models, which were previously developed simulation models, to study the impact of menthol and non-menthol cigarettes on the behavior of traditional cigarettes and e-cigarettes.


A new study has found that with a ban on menthol cigarettes, the combined smoking of both menthol and non-menthol cigarettes will decrease by 15% by 2026. The study also predicts a decrease in smoking and e-cigarette related deaths by approximately 5%. This reduction in deaths would result in a decrease of 16,250 deaths per year over the course of 40 years.


As such, the FDA has recently announced a ban on menthol, which has been a topic of long-standing debate. The negotiation process has been opened, and comments will be accepted until July 5th.


Canada's Ban on Menthol Cigarettes


Data from Canada shows that a local ban on menthol cigarettes has had a positive impact on smoking cessation rates. Research suggests that, given the popularity of menthol cigarettes in the United States, implementing a similar ban in that country would provide even greater benefits. According to Geoffrey Fong, Chief Investigator of the International Tobacco Control Policy Evaluation Project, "Based on our survey results, we estimate that a ban on menthol cigarettes in the US would lead to an additional 923,000 smokers quitting, including 230,000 African American smokers.


Further data confirms the effectiveness of the ban on menthol cigarettes.


Meanwhile, a recent study published in JAMA Internal Medicine found that the ban on menthol-flavored cigarettes in Massachusetts resulted in a statewide decrease in cigarette sales. The study, titled "Massachusetts' Cigarette Sales and Comprehensive Menthol Ban," reported that after the menthol flavor ban went into effect, cigarette sales in Massachusetts dropped by as much as 33%.


According to researchers, during the same period, cigarette sales decreased by 8% in 33 states that did not implement a ban on menthol flavoring, while sales of menthol-flavored cigarettes decreased by 3%. UPI quoted Samuel Asare, co-author of the Sid study, as saying, "We have learned from Massachusetts that the ban on menthol flavoring effectively reduced sales of menthol and overall cigarettes.


This article has been compiled from third-party information for the purpose of educational exchange. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
Indiana’s Foreign-Made Vape Ban Takes Effect, Forcing Brands and Retailers to Adjust Supply Chains
Indiana’s Foreign-Made Vape Ban Takes Effect, Forcing Brands and Retailers to Adjust Supply Chains
A new Indiana law restricting the sale of foreign-made vape products has taken effect, requiring retailers to adjust inventory and sourcing practices. According to The Sun, WDRB and other reports, some local vape shops are reviewing product origins and supplier information to comply with the new requirements. The measure represents a broader shift in U.S. vape regulation, with oversight expanding beyond product authorization and sales rules toward manufacturing origin and supply-chain management.
Jul.24
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
Germany Plans Tobacco Tax Hike, With Cigarette Prices Nearing €12 Per Pack by 2030
Germany Plans Tobacco Tax Hike, With Cigarette Prices Nearing €12 Per Pack by 2030
Germany plans to raise tobacco taxes over the coming years, potentially pushing the average price of a 20-cigarette pack to about €11.78 by 2030. The proposal also covers fine-cut tobacco, cigars, pipe tobacco and e-cigarette liquids.
Jul.14
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
Australia’s TGA Places Nicotine Pouches Under Therapeutic Goods Rules From July 24, Blocking Imports of Unapproved Products
Australia’s TGA Places Nicotine Pouches Under Therapeutic Goods Rules From July 24, Blocking Imports of Unapproved Products
Australia is strengthening controls on nicotine pouches under its existing therapeutic goods regulatory framework. According to the Therapeutic Goods Administration (TGA), nicotine pouch products must meet regulatory requirements, and unapproved products cannot be legally imported. The move follows Australia’s broader approach of maintaining strict oversight of nicotine products, including nicotine-containing vapes. As nicotine pouches expand globally, Australia’s regulatory approach highlights growing differences in how countries manage emerging smoke-free nicotine products.
Regulations
Jul.27